CG Oncology, Inc. (CGON)
D
Pipeline Grade
Financial Position (from SEC Filings)
$33.7M
Cash & Equivalents
$56.9M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$6,636M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase3 Readout | — |
| 2027-03-31 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04452591 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Gue... | PHASE3 | Active Not Recruiting | 190 |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | PHASE3 | Active Not Recruiting | 367 |
| NCT06567743 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | PHASE2 | Recruiting | 325 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.